8-氮杂喹唑啉类化合物作为可穿透血脑屏障的SOS1抑制剂用于癌症治疗
8-Aza Quinazolines as Brain Penetrant SOS1 Inhibitors for Treating Cancer.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2023 Oct 6;14(11):1487-1488. doi: 10.1021/acsmedchemlett.3c00416. eCollection 2023 Nov 9.
Abstract
Provided herein are 8-aza quinazolines as brain-penetrant SOS1 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.
摘要
本文提供了作为可穿透血脑屏障的SOS1抑制剂的8-氮杂喹唑啉类化合物、药物组合物、此类化合物在治疗癌症中的用途以及制备此类化合物的方法。
相似文献
1
8-Aza Quinazolines as Brain Penetrant SOS1 Inhibitors for Treating Cancer.8-氮杂喹唑啉类化合物作为可穿透血脑屏障的SOS1抑制剂用于癌症治疗
ACS Med Chem Lett. 2023 Oct 6;14(11):1487-1488. doi: 10.1021/acsmedchemlett.3c00416. eCollection 2023 Nov 9.
2
Design, synthesis and biological evaluation of quinazoline SOS1 inhibitors.设计、合成及喹唑啉 SOS1 抑制剂的生物评价。
Bioorg Med Chem Lett. 2023 May 15;88:129265. doi: 10.1016/j.bmcl.2023.129265. Epub 2023 Apr 1.
3
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.MRTX0902 的设计与发现：一种强效、选择性、可穿透血脑屏障、口服生物利用度的 SOS1:KRAS 蛋白-蛋白相互作用抑制剂。
J Med Chem. 2022 Jul 28;65(14):9678-9690. doi: 10.1021/acs.jmedchem.2c00741. Epub 2022 Jul 14.
4
Novel Compounds as TEAD Inhibitors for Treating Cancer.用于治疗癌症的新型TEAD抑制剂化合物
ACS Med Chem Lett. 2023 Aug 22;14(9):1152-1153. doi: 10.1021/acsmedchemlett.3c00346. eCollection 2023 Sep 14.
5
Imidazopyridine Compounds as ERK5 Inhibitors for Treating Cancer.作为用于治疗癌症的细胞外信号调节激酶5（ERK5）抑制剂的咪唑并吡啶化合物
ACS Med Chem Lett. 2024 Jun 3;15(6):777-778. doi: 10.1021/acsmedchemlett.4c00228. eCollection 2024 Jun 13.
6
Novel Quinoline Compounds as KRAS Inhibitors for Treating Cancer.新型喹啉化合物作为治疗癌症的KRAS抑制剂
ACS Med Chem Lett. 2023 May 26;14(6):707-708. doi: 10.1021/acsmedchemlett.3c00195. eCollection 2023 Jun 8.
7
Novel Tricyclic Compounds as KRAS Inhibitors for Treating Cancer.新型三环化合物作为治疗癌症的KRAS抑制剂
ACS Med Chem Lett. 2023 Apr 26;14(5):555-556. doi: 10.1021/acsmedchemlett.3c00140. eCollection 2023 May 11.
8
Novel 2,7-Naphthyridine Compounds as MASTL Inhibitors for Treating Cancer.新型2,7-萘啶化合物作为治疗癌症的MASTL抑制剂
ACS Med Chem Lett. 2024 May 1;15(6):748-749. doi: 10.1021/acsmedchemlett.4c00177. eCollection 2024 Jun 13.
9
Novel Heteroaryl Compounds as CD73 Inhibitors for Treating Cancer.新型杂芳基化合物作为用于治疗癌症的CD73抑制剂
ACS Med Chem Lett. 2024 May 31;15(6):775-776. doi: 10.1021/acsmedchemlett.4c00230. eCollection 2024 Jun 13.
10
Novel Pyrazoloquinoline Compounds as KRAS Inhibitors for Treating Cancer.新型吡唑并喹啉化合物作为治疗癌症的KRAS抑制剂
ACS Med Chem Lett. 2023 Jul 25;14(8):1045-1046. doi: 10.1021/acsmedchemlett.3c00300. eCollection 2023 Aug 10.
本文引用的文献
1
Pleckstrin Homology [PH] domain, structure, mechanism, and contribution to human disease.Pleckstrin 同源（PH）结构域：结构、机制及其与人类疾病的关系。
Biomed Pharmacother. 2023 Sep;165:115024. doi: 10.1016/j.biopha.2023.115024. Epub 2023 Jul 1.
2
Development of Son of Sevenless Homologue 1 (SOS1) Modulators To Treat Cancers by Regulating RAS Signaling.通过调节RAS信号通路开发七号无翅型同源物1（SOS1）调节剂用于治疗癌症
J Med Chem. 2023 Apr 13;66(7):4324-4341. doi: 10.1021/acs.jmedchem.2c01729. Epub 2023 Mar 28.
3
Targeting KRAS in colorectal cancer: the beginning of a new era.结直肠癌中 KRAS 的靶向治疗：新时代的开端。
ESMO Open. 2023 Feb;8(1):100745. doi: 10.1016/j.esmoop.2022.100745. Epub 2022 Dec 20.
4
PROTAC therapy as a new targeted therapy for lung cancer.PROTAC 疗法作为一种治疗肺癌的新靶向疗法。
Mol Ther. 2023 Mar 1;31(3):647-656. doi: 10.1016/j.ymthe.2022.11.011. Epub 2022 Nov 22.
5
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.靶向恶性肿瘤中的 RAS 突变：成功、失败及希望所在。
Cancer Commun (Lond). 2023 Jan;43(1):42-74. doi: 10.1002/cac2.12377. Epub 2022 Oct 31.
6
Targeting Son of Sevenless 1: The pacemaker of KRAS.靶向 Sevenless 同源物 1：KRAS 的起搏器。
Curr Opin Chem Biol. 2021 Jun;62:109-118. doi: 10.1016/j.cbpa.2021.02.014. Epub 2021 Apr 10.
Zotero 插件